|
|
News Breaks | | | | September 21, 2012 | | 09:00 EDT |  | VVUS | VIVUS falls 13.4%
VIVUS is down 13.4%, or $3.17, to $20.55 | |
|
News For VVUS From The Last 14 Days Check below for free stories on VVUS the last two weeks. |
|
|
| June 19, 2013 | | 12:22 EDT |  | VVUS | Outlook for obesity drug coverage has improved, says Leerink
Leerink notes that the VA started covering Vivus' (VVUS) Qsymia in April, while a bipartisan group of lawmakers will introduce a bill today to make Medicare begin covering weight-loss drugs. Meanwhile the AMA has labeled obesity a disease for the first time, Leerink added. The firm believes that the community will begin treating obesity as a disease, and it thinks that recent events could enable weight loss drug makers to exceed its estimates. The firm reiterates Outperform ratings on weight loss drug makers Vivus, Arena (ARNA), and Orexigen (OREX). | | | 09:49 EDT |  | VVUS | Weight loss drug makers rise after AMA calls obesity a disease
Makers of anti-obesity drugs are advancing after the American Medical Association designated obesity as a disease. WHAT'S NEW: The AMA recognized obesity as a disease yesterday. Obesity "requires a range of medical interventions," and the treatment and prevention of the condition must be advanced, the organization stated. The AMA's decision will help change the way doctors deal with obesity, AMA board member Patrice Harris, M.D, stated. TODAY'S PRICE ACTION: In early trading, Arena Pharmaceuticals (ARNA) rose 2% to $7.65, while VIVUS (VVUS) climbed 2.4% to $14.10 and Orexigen (OREX) inched up 0.3% to $6.40. | | | 09:24 EDT | | VVUS | On The Fly: Pre-market Movers
 Subscribe for More Information | | | 07:11 EDT | | VVUS | VIVUS study of Stendra shows efficacy within 15 minutes in men with ED
VIVUS announced positive results from a multicenter, placebo-controlled study, TA-501, designed to assess the efficacy of Stendra in approximately 15 minutes. In the study, Stendra patients achieved statistically significant improvement over placebo, in the mean proportion of attempts that resulted in erections sufficient for successful intercourse, as early as 10 minutes for the 200 mg dose and 12 minutes for the 100 mg dose after being taken. | | | 06:52 EDT |  | VVUS | AMA recognizes obesity as disease. NY Times reports
The American Medical Association, or AMA, has officially recognized obesity as a disease, The New York Times reported yesterday. The decision could cause more insurance companies to pay for obesity treatments and spur more doctors to take more steps to combat the condition, the newspaper stated. The AMA overrode a recommendation by a committee that had recommended against making the change, the newspaper noted. Reference Link | | | June 17, 2013 | | 07:11 EDT | | VVUS | VIVUS urges stockholders to vote on the GOLD proxy card
VIVUS mailed a letter to stockholders advising them to protect the value of their investment in VIVUS by voting the GOLD proxy card. The letter stated "VIVUS stockholders face an important decision at the upcoming 2013 VIVUS Annual Meeting of Stockholders. Your board and management team have made substantial progress in laying the foundation for Qsymia, and now we are poised to drive future sales by providing broad access to the millions of patients whose lives would benefit from this important therapy. While much progress has already been made, careful and timely execution of the next phase of our retail commercialization plan will be critical to the success of VIVUS. This phase of our retail commercialization plan, after REMS modification, requires a major pharmaceutical company to reach the primary care physicians. As such, we are in discussions with large pharmaceutical companies to explore opportunities as to how we may work together to maximize sales of Qsymia. We strongly believe that electing First Manhattan nominees at the Annual Meeting will jeopardize the progress we are making, and will throw VIVUS into turmoil. At this critical juncture in the company's history, FMC, which owns less than 10% of the company's stock, is trying to seize control of 100% of the VIVUS Board and your company. We strongly urge you not to jeopardize the important progress your Board and management team are making and risk your investment." | | | June 7, 2013 | | 07:04 EDT | | VVUS | VIVUS drug Qsymia cited in The Journal of Diabetes and Its Complications
Subscribe for More Information | |
|
|
|
|
|
|
